I25.752

Clinical Causes: Progressive buildup of cholesterol and other substances within the transplanted heart’s native coronary arteries. Accelerated atherosclerosis due to immune responses and medication side effects post-transplant. Contributing factors such as high blood pressure, high cholesterol levels, smoking, diabetes, and obesity. Chronic low-grade inflammation within the blood vessels after transplantation can promote arterial plaque formation. Immunosuppressive medications used to prevent transplant rejection may influence lipid levels and vascular health.

Key Symptoms: Persistent or worsening chest pain known as refractory angina pectoris. Shortness of breath, especially during physical activity. Fatigue and general weakness. Symptoms of heart failure, such as swelling of legs and ankles. Occasional dizziness or fainting episodes. Possible silent ischemia where symptoms are minimal or absent despite reduced blood flow.

Diagnosis Path: Coronary angiography to visualize blockages or narrowing in coronary arteries. Non-invasive tests such as stress tests, echocardiograms, or cardiac MRI. Blood tests to evaluate cholesterol and other cardiovascular risk factors. Intravascular ultrasound (IVUS) to assess the extent of arterial plaque formation. Monitoring clinical symptoms and repeat imaging studies over time for disease progression.

Treatment Protocols: Medication management including nitrates, beta-blockers, calcium channel blockers, and antiplatelet agents to control angina and reduce clot formation. Lipid-lowering therapies such as statins to manage cholesterol levels. Adjustment of immunosuppressive medications to minimize vascular side effects while preventing rejection. Percutaneous coronary interventions (PCI), such as angioplasty and stenting, to open narrowed arteries. Coronary artery bypass grafting (CABG) in select cases with extensive disease. Regular follow-up and monitoring to assess disease progression and optimize therapy.